Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 261

1.

Correlation of tumor burden in sentinel lymph nodes with tumor burden in non-sentinel lymph nodes and survival in cutaneous melanoma.

Namikawa K, Aung PP, Milton DR, Tetzlaff MT, Torres Cabala CA, Curry JL, Nagarajan P, Ivan D, Ross MI, Gershenwald JE, Prieto VG.

Clin Cancer Res. 2019 Sep 30. pii: clincanres.1194.2019. doi: 10.1158/1078-0432.CCR-19-1194. [Epub ahead of print]

PMID:
31570567
2.

Enhancing Case Capture, Quality, and Completeness of Primary Melanoma Pathology Records via Natural Language Processing.

Malke JC, Jin S, Camp SP, Lari B, Kell T, Simon JM, Prieto VG, Gershenwald JE, Haydu LE.

JCO Clin Cancer Inform. 2019 Aug;3:1-11. doi: 10.1200/CCI.19.00006.

3.

Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features.

Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MT.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0340-7. [Epub ahead of print]

PMID:
31383963
4.

Isolated Imunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System.

Scolyer RA, Gershenwald JE, Thompson JF.

Am J Surg Pathol. 2019 Oct;43(10):1442-1444. doi: 10.1097/PAS.0000000000001326. No abstract available.

PMID:
31306154
5.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
6.

Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression.

Fang S, Xu T, Xiong M, Zhou X, Wang Y, Haydu LE, Ross MI, Gershenwald JE, Prieto VG, Cormier JN, Wargo J, Sui D, Wei Q, Amos CI, Lee JE.

J Invest Dermatol. 2019 Jun 7. pii: S0022-202X(19)31626-4. doi: 10.1016/j.jid.2019.03.1158. [Epub ahead of print]

PMID:
31176707
7.

Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility.

Lillemoe HA, Scally CP, Adams CL, Bednarski BK, Balch CM, Aloia TA, Gershenwald JE, Lee JE, Grubbs EG.

Ann Surg Oncol. 2019 Sep;26(9):2667-2674. doi: 10.1245/s10434-019-07420-w. Epub 2019 Jun 5.

PMID:
31168736
8.

Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system.

Haydu LE, Thompson JF, Scolyer RA, Gershenwald JE.

Eur J Cancer. 2019 May;112:9-11. doi: 10.1016/j.ejca.2019.01.103. Epub 2019 Mar 15. No abstract available.

PMID:
30884440
9.

Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers.

Dessinioti C, Dimou N, Geller AC, Stergiopoulou A, Lo S, Keim U, Gershenwald JE, Haydu LE, Ribero S, Quaglino P, Puig S, Malvehy J, Kandolf-Sekulovic L, Radevic T, Kaufmann R, Meister L, Nagore E, Traves V, Champsas GG, Plaka M, Dreno B, Varey E, Ramirez DM, Dummer R, Mangana J, Hauschild A, Egberts F, Peris K, Del Regno L, Forsea AM, Zurac SA, Vieira R, Brinca A, Zalaudek I, Deinlein T, Linos E, Evangelou E, Thompson JF, Scolyer RA, Garbe C, Stratigos AJ.

J Natl Cancer Inst. 2019 Mar 13. pii: djz034. doi: 10.1093/jnci/djz034. [Epub ahead of print]

PMID:
30863861
10.

Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.

Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA.

Cancer Discov. 2019 May;9(5):628-645. doi: 10.1158/2159-8290.CD-18-1489. Epub 2019 Feb 20.

PMID:
30787016
11.

Completion Node Dissection for Sentinel Node-Positive Melanoma: Can a Systematic Review Bring One Discussion to a Close While Leaving the Broader Conversation Still Open?

Berman RS, Gershenwald JE.

Ann Surg Oncol. 2019 Apr;26(4):921-923. doi: 10.1245/s10434-019-07211-3. Epub 2019 Feb 8. No abstract available.

PMID:
30737667
12.

Setting the "stage" for Surgical Oncology fellows: Pierre Denoix and TNM staging.

Asare EA, Grubbs EG, Gershenwald JE, Greene FL, Aloia TA.

J Surg Oncol. 2019 Jun;119(7):823. doi: 10.1002/jso.25404. Epub 2019 Feb 6. No abstract available.

PMID:
30729519
13.

Telementoring and smartphone-based answering systems to optimize dermatology resident dermoscopy education.

Nelson KC, Gershenwald JE, Savory SA, Wilson JM, Simon JM, Burton EM, Haydu LE.

J Am Acad Dermatol. 2019 Aug;81(2):e27-e28. doi: 10.1016/j.jaad.2019.01.045. Epub 2019 Jan 29. No abstract available.

PMID:
30703459
14.

Staging of Cutaneous Melanoma: Is There Room for Further Improvement?

Ferguson PM, Gershenwald JE, Scolyer RA.

JAMA Netw Open. 2018 May 18;1(1):e180086. doi: 10.1001/jamanetworkopen.2018.0086. No abstract available.

PMID:
30646045
15.

Guidelines of care for the management of primary cutaneous melanoma.

Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, Sober AJ, Thompson JA, Wisco OJ, Wyatt S, Hu S, Lamina T.

J Am Acad Dermatol. 2019 Jan;80(1):208-250. doi: 10.1016/j.jaad.2018.08.055. Epub 2018 Nov 1.

PMID:
30392755
16.

Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB.

Cancer. 2019 Jan 1;125(1):18-44. doi: 10.1002/cncr.31719. Epub 2018 Oct 3. Review. Erratum in: Cancer. 2019 Aug 1;125(15):2706.

PMID:
30281145
17.

A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node.

Bhutiani N, Egger ME, Stromberg AJ, Gershenwald JE, Ross MI, Philips P, Martin RCG 2nd, Scoggins CR, McMasters KM.

J Surg Oncol. 2018 Nov;118(6):922-927. doi: 10.1002/jso.25193. Epub 2018 Sep 27.

PMID:
30259521
18.

Lifestyle Modifications and Policy Implications for Primary and Secondary Cancer Prevention: Diet, Exercise, Sun Safety, and Alcohol Reduction.

LoConte NK, Gershenwald JE, Thomson CA, Crane TE, Harmon GE, Rechis R.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:88-100. doi: 10.1200/EDBK_200093. Review.

PMID:
30231343
19.

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.

Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE.

Cancer Res. 2018 Oct 1;78(19):5680-5693. doi: 10.1158/0008-5472.CAN-18-1001. Epub 2018 Aug 16.

20.

Correction to: Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond.

Gershenwald JE, Scolyer RA.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):993-994. doi: 10.1245/s10434-018-6689-x.

PMID:
30105437
21.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA.

Ann Oncol. 2018 Aug 1;29(8):1861-1868. doi: 10.1093/annonc/mdy226.

22.

The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care.

Keung EZ, Gershenwald JE.

Expert Rev Anticancer Ther. 2018 Aug;18(8):775-784. doi: 10.1080/14737140.2018.1489246. Review.

PMID:
29923435
23.

Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall.

Curry JL, Tetzlaff MT, Wang SA, Landon G, Alouch N, Patel SP, Nagarajan P, Gupta S, Aung PP, Devine CE, Khoury JD, Loghavi S, Prieto VG, DiNardo CD, Gershenwald JE.

Am J Dermatopathol. 2018 Nov;40(11):831-835. doi: 10.1097/DAD.0000000000001150.

PMID:
29863571
24.

Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond.

Gershenwald JE, Scolyer RA.

Ann Surg Oncol. 2018 Aug;25(8):2105-2110. doi: 10.1245/s10434-018-6513-7. Epub 2018 May 30. No abstract available. Erratum in: Ann Surg Oncol. 2018 Dec;25(Suppl 3):993-994.

PMID:
29850954
25.

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C.

Clin Cancer Res. 2018 Sep 15;24(18):4416-4428. doi: 10.1158/1078-0432.CCR-17-3649. Epub 2018 May 30.

26.

Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma.

Bezrookove V, Nosrati M, Miller JR 3rd, De Semir D, Dar AA, Vosoughi E, Vaquero E, Sucker A, Lazar AJ, Gershenwald JE, Davies MA, Schadendorf D, Kashani-Sabet M.

Clin Cancer Res. 2018 Sep 1;24(17):4119-4125. doi: 10.1158/1078-0432.CCR-18-0791. Epub 2018 May 18.

27.

The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.

Ascierto PA, Caracò C, Gershenwald JE, Hamid O, Ross M, Sullivan RJ, Puzanov I.

J Transl Med. 2018 Apr 17;16(1):101. doi: 10.1186/s12967-018-1477-8.

28.

Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors.

Zabor EC, Coit D, Gershenwald JE, McMasters KM, Michaelson JS, Stromberg AJ, Panageas KS.

Ann Surg Oncol. 2018 Aug;25(8):2172-2177. doi: 10.1245/s10434-018-6370-4. Epub 2018 Feb 22.

30.

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA.

Lancet Oncol. 2018 Mar;19(3):310-322. doi: 10.1016/S1470-2045(18)30078-0. Epub 2018 Feb 12.

31.

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA.

Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.

PMID:
29361468
32.

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.

Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT; TCGA Research Network, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE.

Cancer Cell. 2018 Jan 8;33(1):151. doi: 10.1016/j.ccell.2017.12.013. No abstract available.

33.

Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas.

Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, Davies MA, Lazar AJ, Gershenwald JE.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00259. Epub 2018 Jun 14.

34.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.

Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.

35.

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform.

CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.

36.

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA.

NPJ Genom Med. 2017;2. pii: 10. doi: 10.1038/s41525-017-0013-8. Epub 2017 Apr 7.

37.

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.

Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT; TCGA Research Network, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE.

Cancer Cell. 2017 Aug 14;32(2):204-220.e15. doi: 10.1016/j.ccell.2017.07.003. Erratum in: Cancer Cell. 2018 Jan 8;33(1):151.

38.

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM.

N Engl J Med. 2017 Jun 8;376(23):2211-2222. doi: 10.1056/NEJMoa1613210.

39.

Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes.

Fang S, Wang Y, Dang Y, Gagel A, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Haydu LE, Davies MA, McQuade JL, Sui D, Bassett RL, Reveille JD, Wei Q, Amos CI, Lee JE.

J Invest Dermatol. 2017 Aug;137(8):1792-1795. doi: 10.1016/j.jid.2017.04.007. Epub 2017 Apr 23. No abstract available.

40.

Skin Cancer: Have melanoma and skin cancer finally met their match?

Gershenwald JE, Nelson KC.

Nat Rev Clin Oncol. 2017 May;14(5):267-268. doi: 10.1038/nrclinonc.2017.55. Epub 2017 Apr 19. No abstract available.

PMID:
28422116
41.

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA.

Sci Transl Med. 2017 Mar 1;9(379). pii: eaah3560. doi: 10.1126/scitranslmed.aah3560. Erratum in: Sci Transl Med. 2017 Apr 12;9(385):.

42.

The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP.

CA Cancer J Clin. 2017 Mar;67(2):93-99. doi: 10.3322/caac.21388. Epub 2017 Jan 17.

43.

Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy.

Roife D, Kang Y, Wang L, Fang B, Swisher SG, Gershenwald JE, Pretzsch S, Dinney CP, Katz MHG, Fleming JB.

Surgery. 2017 May;161(5):1246-1254. doi: 10.1016/j.surg.2016.11.020. Epub 2017 Jan 9.

44.

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.

Kim DW, Haydu LE, Joon AY, Bassett RL Jr, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA.

Cancer. 2017 Apr 15;123(8):1372-1381. doi: 10.1002/cncr.30463. Epub 2016 Dec 2.

45.

Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases.

Nagarajan P, Curry JL, Ning J, Piao J, Torres-Cabala CA, Aung PP, Ivan D, Ross MI, Levenback CF, Frumovitz M, Gershenwald JE, Davies MA, Malpica A, Prieto VG, Tetzlaff MT.

Clin Cancer Res. 2017 Apr 15;23(8):2093-2104. doi: 10.1158/1078-0432.CCR-16-2126. Epub 2016 Nov 18.

46.

Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors.

Tripp MK, Gershenwald JE, Davies MA, Garcia J, Gritz ER, Hawk ET, Peterson SK.

JAMA Dermatol. 2017 Feb 1;153(2):228-229. doi: 10.1001/jamadermatol.2016.4068. No abstract available.

47.

Melanoma Prevention-Avoiding Indoor Tanning and Minimizing Overexposure to the Sun.

Gershenwald JE, Halpern AC, Sondak VK.

JAMA. 2016 Nov 8;316(18):1913-1914. doi: 10.1001/jama.2016.16430. No abstract available.

PMID:
27824997
48.

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE.

BMC Med. 2016 Oct 25;14(1):168.

49.

Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness.

Fang S, Vaysse A, Brossard M, Wang Y, Deng D, Liu Q, Zhang P, Xu K, Li M, Feng R, Liu H, Dang Y, Chen W, Prieto V, Gershenwald JE, Ross MI, Matejka B, Malke J, Haydu LE, Reveille JD, Sui D, Bassett RL Jr, Koshkina N, Avril MF, Lu M, Wei Q, Demenais F, Amos CI, Lee JE.

J Invest Dermatol. 2017 Jan;137(1):253-257. doi: 10.1016/j.jid.2016.07.032. Epub 2016 Aug 6. No abstract available.

50.

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA.

Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14.

Supplemental Content

Loading ...
Support Center